Company

Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion

CompanyDeals

3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development

CompanyDeals

Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion

CompanyDrug

Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE

CompanyDrug

EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma

CompanyDrug

Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients

CompanyDeals

Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101

CompanyDrug

Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke

CompanyDrug

Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer

CompanyDeals

Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF

CompanyDrug

Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors

CompanyDeals

Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong